Rezlidhia (Olutasidenib)

Rezlidhia (Olutasidenib)

Rezlidhia

Olutasidenib

Capsules: 150 mg

Rigel and Forma Therapeutics, Inc.

Medical Use

Rezlidhia (olutasidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor used to treat adults with IDH1-mutated Acute Myeloid Leukemia (AML) when the cancer has relapsed or has not responded to previous treatments.

Recommended Dosage: The suggested dosage is 150 mg taken orally twice daily until the disease progresses or unacceptable toxicity occurs. Take Rezlidhia capsules at approximately the same time each day. Ensure there is at least an 8-hour gap between doses. Consume on an empty stomach, either 60 minutes before or 120 minutes after a meal. Swallow the capsules whole without opening, breaking, or chewing them. For patients without disease progression or unacceptable toxicity, continue treatment for at least 6 months to allow for a clinical response.

If a dose is vomited, do not take an additional dose; wait until the next scheduled dose. If a dose is missed or not taken at the usual time, take it as soon as possible, ensuring there is at least an 8-hour gap before the next dose. Resume the regular dosing schedule the following day.